• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma

byDaniel GoldshteinandSze Wah Samuel Chan
August 19, 2024
in Chronic Disease, Oncology
Reading Time: 3 mins read
VEGFR-targeted ultrasound may improve detection of pancreatic cancer
Share on FacebookShare on TwitterShare on LinkedIn

1. The median progression-free survival in the metastasis-directed therapy arm was 10.3 months vs 2.5 months in the control arm with an HR of 0.43 (significant).

2. Baseline CA19-9 level were found to be prognostic, ≥90 U/mL compared to<90 U/mL had an HR 2.96 (significant).

Evidence Rating Level: 1 (Excellent)

Study Rundown: Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have poor outcomes after frontline chemotherapy however for patients with oligometastatic PDAC, some evidence exists for combining chemotherapy with metastasis-directed therapy (MDT) to improve outcomes. This study further explored whether adding MDT to systemic therapy could improve outcomes in these patients. The primary endpoint was progression-free survival (PFS) and secondary endpoints included overall survival (OS), time to next-line systemic therapy, time to local failure, time to new lesion formation, toxicity, and quality of life (QoL). There were also some exploratory endpoints which investigated measures of systemic immune response with MDT. Median PFS in the MDT arm was 10.3 months vs 2.5 months in the control arm with an HR 0.43 (p=0.030). PFS rates at 1 year were 42% in the MDT arm and 9% in the control arm. A post hoc analysis found baseline CA19-9 level as prognostic, ≥90 U/mL compared to <90 U/mL, with an HR 2.96 (p=0.004). When analyzed for PFS, MDT for patients with CA19-9 <90 U/mL had an HR 0.33 (p=0.06) compared with CA19-9 ≥90 U/mL with an HR 0.37 (p=0.048). The median time to new lesion recurrence was 14 months in the MDT arm vs 5 months in the control arm with an HR 0.51 (p=0.22). The median time to next-line systemic therapy was 19 months in the MDT arm vs 8 months in the control arm with an HR 0.53 (p=0.24). The median OS for the MDT arm was 12 months vs 10 months in the control arm with an HR 0.58 (p=0.20). QoL comparisons showed no apparent differences. Exploratory endpoints for the systemic immune response of MDT found that proliferative CD8 T cells were greater at follow-up in the MDT arm compared with the control arm (p=0.02), and that some markers of T-cell activated were associated with improved PFS and OS. The strengths of this study included its methodology and the limitations included the sample size. Overall, this study found that adding MDT to systemic therapy had some improved outcomes compared with systemic therapy alone in oligometastatic PDAC.

Click to read the study in the JCO (Journal of Clinical Oncology)

Relevant Reading: Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer The EXTEND Phase 2 Randomized Clinical Trial

RELATED REPORTS

Daraxonrasib extends survival in metastatic pancreatic cancer

Younger age and systemic metastases may independently predict survival among patients with choroidal metastases

FDA approvedFor pancreatic ductal adenocarcinoma: Rasonque (daraxonrasib), Aug 26, 2026→

In-Depth [randomized controlled trial]: This multicenter phase II basket trial enrolled adults with PDAC with less than 5 sites of metastatic disease amenable to MDT and randomized them (1:1) to MDT with systemic therapy (n = 20) vs systemic therapy alone (n = 21). MDT consisted of definitive local therapy such as stereotactic ablative radiotherapy with the most common prescriptions being 50 Gy in 4 fractions or 70 Gy in 10 fractions. The systemic therapy was chosen by the treating oncologist and the most common therapy was GA-based chemotherapy. Most patients (78%) had 1 or 2 metastases at baseline. Median follow-up of 17.3 months. Median PFS in the MDT arm was 10.3 months (95%CI, 4.6-14.0) vs 2.5 months in the control arm (95%CI, 1.7-5.1) with an HR 0.43 (95%CI, 0.20-0.94, p=0.030). PFS rates at 1 year were 42% (95%CI, 19-64) in the MDT arm and 9% (95%CI, 1-29) in the control arm. A post hoc analysis found baseline CA19-9 level as prognostic, ≥90 U/mL compared to <90 U/mL, with an HR 2.96 (95%CI, 1.40-6.24, p=0.004). When analyzed for PFS, MDT for patients with CA19-9 <90 U/mL had an HR 0.33 (95%CI, 0.11-1.05, p=0.06) compared with CA19-9 ≥90 U/mL with an HR 0.37 (95%CI, 0.14-0.99, p=0.048). The median time to new lesion recurrence was 14 months in the MDT arm (95%CI, 6-NA) vs 5 months in the control arm (95%CI, 3-NA) with an HR 0.51 (95%CI, 0.18-1.49, p=0.22). The median time to next-line systemic therapy was 19 months in the MDT arm (95%CI, 8-NA) vs 8 months in the control arm (95%CI, 3-NA) with an HR 0.53 (95%CI, 0.19-1.51, p=0.24). The median OS for the MDT arm was 12 months (95%CI, 8-23) vs 10 months in the control arm (95%CI, 7-NA) with an HR 0.58 (95%CI, 0.25-1.34, p=0.20). QoL comparisons showed no apparent differences. Exploratory endpoints for the systemic immune response of MDT found that proliferative CD8 T cells were greater at follow-up in the MDT arm compared with the control arm (p=0.02) and that some markers of T-cell activation were associated with improved PFS and OS. Overall, this study found that adding MDT to systemic therapy had some improved outcomes compared with systemic therapy alone in oligometastatic PDAC.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: metastasespancreatic adenocarcinomaSBRT
Previous Post

#VisualAbstract: A Vaping Cessation Text Message Program Reduces Adolescent E-Cigarette Users

Next Post

Alternative lung cancer screening criteria may increase sensitivity versus current guidelines

RelatedReports

The image features a woman examining samples under a microscope, representations of cancer cells, a knee joint, and a liver with a pill at the center, suggesting a focus on oncology and pharmaceutical therapy.
Oncology

Daraxonrasib extends survival in metastatic pancreatic cancer

September 17, 2026
Eye disease collage: an engraved slit-lamp microscope casting a pale beam, with folded reading glasses on graph paper
Chronic Disease

Younger age and systemic metastases may independently predict survival among patients with choroidal metastases

August 3, 2026
Low back pain collage: a wooden chair with a lumbar cushion and folded heat wrap beside an engraved lumbar vertebra
Chronic Disease

Spinal instability may be the primary cause of pain in sacral metastases as opposed to neurologic compromise

July 14, 2026
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Weekly Rewinds

2 Minute Medicine Rewind July 13, 2026

July 13, 2026
Next Post

Alternative lung cancer screening criteria may increase sensitivity versus current guidelines

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!

The Scan by 2 Minute Medicine®: Competition and COVID, Anti-Anaphylaxis, Pulling the Plug on Psychedelics and POTS in the Pool:

#VisualAbstract Molecular Guided Therapy Improves Survival for Unfavourable Cancer of Unknown Origin

#VisualAbstract Molecular Guided Therapy Improves Survival for Unfavourable Cancer of Unknown Origin

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • ADCE-D01 showed a 30% objective response rate in topline phase 1 results for previously treated advanced soft tissue sarcoma
  • Less social media usage is associated with improved internalizing symptoms in high-risk young adults.
  • AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.